COST ACCOUNTING W18 CUSTOM W/ACCESS
COST ACCOUNTING W18 CUSTOM W/ACCESS
18th Edition
ISBN: 9781323831427
Author: Horngren
Publisher: PEARSON
bartleby

Concept explainers

bartleby

Videos

Textbook Question
Book Icon
Chapter 1, Problem 1.34P

Budgeting, ethics, pharmaceutical company. Chris Jackson was recently promoted to Controller of Research and Development (R&D) for BrisCor, a Fortune 500 pharmaceutical company that manufactures prescription drugs and nutritional supplements. The company’s total R&D cost for 2017 was expected (budgeted) to be $5 billion. During the company’s midyear budget review, Chris realized that current R&D expenditures were already at $3.5 billion, nearly 40% above the midyear target. At this current rate of expenditure, the R&D division was on track to exceed its total year-end budget by $2 billion!

In a meeting with CFO Ronald Meece later that day, Jackson delivered the bad news. Meece was both shocked and outraged that the R&D spending had gotten out of control. Meece wasn’t any more understanding when Jackson revealed that the excess cost was entirely related to research and development of a new drug, Vyacon, which was expected to go to market next year. The new drug would result in large profits for BrisCor, if the product could be approved by year-end.

Meece had already announced his expectations of third-quarter earnings to Wall Street analysts. If the R&D expenditures weren’t reduced by the end of the third quarter, Meece was certain that the targets he had announced publicly would be missed and the company’s stock price would tumble. Meece instructed Jackson to make up the budget shortfall by the end of the third quarter using “whatever means necessary.”

Jackson was new to the controller’s position and wanted to make sure that Meece’s orders were followed. Jackson came up with the following ideas for making the third-quarter budgeted targets:

  1. a. Stop all research and development efforts on the drug Vyacon until after year-end. This change would delay the drug going to market by at least 6 months. It is possible that in the meantime a BrisCor competitor could make it to market with a similar drug.
  2. b. Sell off rights to the drug Martek. The company had not planned on doing this because, under current market conditions, it would get less than fair value. It would, however, result in a one-time gain that could offset the budget shortfall. Of course, all future profits from Martek would be lost.
  3. c. Capitalize some of the company’s R&D expenditures, reducing R&D expense on the income statement. This transaction would not be in accordance with GAAP, but Jackson thought it was justifiable because the Vyacon drug was going to market early next year. Jackson would argue that capitalizing R&D costs this year and expensing them next year would better match revenues and expenses.
  4. 1. Referring to the “Standards of Ethical Behavior for Practitioners of Management Accounting and Financial Management,” Figure 1-7 (page 17),which of the preceding items (a–c) are acceptable to use? Which are unacceptable?

Required

  1. 2. What would you recommend Jackson do?
Blurred answer
Students have asked these similar questions
Budgeting, ethics, pharmaceutical company.  Chris Jackson was recently promoted to Controller of Research and Development  for BrisC or, a Fortune  500 pharmaceutical company that manufactures prescription drugs and nutritional supplements. The company’s total R&amp ; D cost for 2017 was expected (budgeted) to be $5 billion. During the company’s midyear budget review, Chris realized that current R&amp ; D expenditures were already at $3.5 billion, nearly 40% above the midyear target. At this current rate of expenditure, the R&amp ; D division was on track to exceed its total year-end budget by $2 billion! In a meeting with CFO Ronald Meece later that day, Jackson delivered the bad news. Meece was both shocked and outraged that the R&D spending had gotten out of control. Meece wasn’t any more understanding when Jackson revealed that the excess cost was entirely related to research and development of a new drug, Vyacon, which was expected to go to market next year.…
Chris Jackson was recently promoted to Controller ofResearch and Development (R&D) for BrisCor, a Fortune 500 pharmaceutical company that manufacturesprescription drugs and nutritional supplements. The company’s total R&D cost for 2017 was expected (budgeted)to be $5 billion. During the company’s midyear budget review, Chris realized that current R&D expenditureswere already at $3.5 billion, nearly 40% above the midyear target. At this current rate of expenditure,the R&D division was on track to exceed its total year-end budget by $2 billion!In a meeting with CFO Ronald Meece later that day, Jackson delivered the bad news. Meece was bothshocked and outraged that the R&D spending had gotten out of control. Meece wasn’t any more understandingwhen Jackson revealed that the excess cost was entirely related to research and development of anew drug, Vyacon, which was expected to go to market next year. The new drug would result in large profitsfor BrisCor, if the product…
McGuire prepares budgets to help manage the company. McGuire is budgeting forthe fiscal year ended January 31, 2016. During the preceding year ended January 31, 2015, salestotaled $9,500 million and cost of goods sold was $6,300 million. At January 31, 2015, inventorywas $1,800 million. During the upcoming 2016 year, suppose McGuire expects cost of goodssold to increase by 10%. The company budgets next year’s ending inventory at $2,100 million.Requirement1. One of the most important decisions a manager makes is how much inventory to buy. Howmuch inventory should McGuire purchase during the upcoming year to reach its budget?

Chapter 1 Solutions

COST ACCOUNTING W18 CUSTOM W/ACCESS

Knowledge Booster
Background pattern image
Accounting
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, accounting and related others by exploring similar questions and additional content below.
Similar questions
SEE MORE QUESTIONS
Recommended textbooks for you
Text book image
Cornerstones of Cost Management (Cornerstones Ser...
Accounting
ISBN:9781305970663
Author:Don R. Hansen, Maryanne M. Mowen
Publisher:Cengage Learning
Text book image
Managerial Accounting
Accounting
ISBN:9781337912020
Author:Carl Warren, Ph.d. Cma William B. Tayler
Publisher:South-Western College Pub
Text book image
Principles of Cost Accounting
Accounting
ISBN:9781305087408
Author:Edward J. Vanderbeck, Maria R. Mitchell
Publisher:Cengage Learning
Text book image
Fundamentals Of Financial Management, Concise Edi...
Finance
ISBN:9781337902571
Author:Eugene F. Brigham, Joel F. Houston
Publisher:Cengage Learning
Text book image
EBK CONTEMPORARY FINANCIAL MANAGEMENT
Finance
ISBN:9781337514835
Author:MOYER
Publisher:CENGAGE LEARNING - CONSIGNMENT
Responsibility Accounting| Responsibility Centers and Segments| US CMA Part 1| US CMA course; Master Budget and Responsibility Accounting-Intro to Managerial Accounting- Su. 2013-Prof. Gershberg; Author: Mera Skill; Rutgers Accounting Web;https://www.youtube.com/watch?v=SYQ4u1BP24g;License: Standard YouTube License, CC-BY